APGE
NASDAQ HealthcareApogee Therapeutics, Inc. - Common Stock
Biotechnology
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
๐ Market Data
| Price | $134.08 |
|---|---|
| Volume | 1,286,603 |
| Market Cap | 10.08B |
| Beta | 0.330 |
| RSI (14-Day) | 76.3 Overbought |
| 200-Day MA | $77.98 |
| 50-Day MA | $101.37 |
| 52-Week High | $134.32 |
| 52-Week Low | $34.34 |
| Forward P/E | -25.84 |
| Price / Book | 7.95 |
๐ฏ Investment Strategy Scores
APGE scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (91/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Moon Shot (5/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find APGE in your text
Paste any article, transcript, or post โ the tool will extract APGE and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.